AYTU BIOPHARMA, INC Stock or Unit Option Plan Expense
AYTU BIOPHARMA, INC (AYTU) reported Stock or Unit Option Plan Expense of $139.00 thousand for the 12-month period ending 2018-06-30, per its 10-K filed 2018-09-06.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:StockOptionPlanExpense · last filed 2018-09-06
- AYTU BIOPHARMA, INC stock or unit option plan expense for the quarter ending 2018-06-30 was $50.00K.
- AYTU BIOPHARMA, INC stock or unit option plan expense for the quarter ending 2017-03-31 was $816.86K, a 175.76% increase year-over-year.
- AYTU BIOPHARMA, INC stock or unit option plan expense for the quarter ending 2016-12-31 was $381.42K, a 108.92% increase year-over-year.
- AYTU BIOPHARMA, INC stock or unit option plan expense for the quarter ending 2016-09-30 was $1.04M, a 1427.64% increase year-over-year.
- AYTU BIOPHARMA, INC stock or unit option plan expense for fiscal 2018 was $139.00K.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 6 month | Stock or Unit Option Plan Expense 9 month | Stock or Unit Option Plan Expense 12 month |
|---|---|---|---|---|
| 2018-06-30 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06 | $139.00K 10-K · filed 2018-09-06 | ||
| 2018-03-31 | $89.00K 10-Q · filed 2018-05-14 | |||
| 2017-03-31 | $816.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-11 | $1.20M derived: sum of 2 quarters · filed 2017-05-11 | $2.24M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $381.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $1.43M 10-Q · filed 2017-02-09 | ||
| 2016-09-30 | $1.04M 10-Q · filed 2016-11-07 | |||
| 2016-03-31 | $296.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-11 | $478.79K derived: sum of 2 quarters · filed 2017-05-11 | $547.11K 10-Q · filed 2017-05-11 | |
| 2015-12-31 | $182.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $250.89K 10-Q · filed 2017-02-09 | ||
| 2015-09-30 | $68.32K 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |